NEUROTECH INTERNATIONAL LIMITED, OR NEUROTECH, IS A MEDICAL DEVICE AND SOLUTIONS COMPANY INCORPORATED IN AUSTRALIA, OPERATING THROUGH ITS WHOLLY-OWNED, MALTA-BASED SUBSIDIARY, AAT RESEARCH LIMITED.
Our primary mission is to improve the lives of people with neurological conditions, with a vision of becoming the global leader in home-use and clinical neurotechnology solutions which are accessible and affordable. Through our first flagship medical device, Mente Autism, and the associated software platform, Neurotech is focused on the development and commercialisation of technological solutions for the diagnosis and treatment of such conditions, starting with autism. The development of the Mente Autism headband, now in its third iteration, represents years of research, testing and pilot studies, to effectively bring a highly specialised treatment for the management of autism, from the hospitals and clinics, into the comfort and familiarity of a patient’s home.
In doing so, Neurotech and the Mente technology sit at the confluence of several market forces, including a heightened focus on understanding the brain, the increasing diagnosis of neurological conditions and the increasing adoption of home-based precision healthcare.